Novel Therapy Shows Promising Results In On-Going Trials, Receives 3 Orphan Drug Designations From The FDA
- 3 months ago
Vlad Vitoc, MD, MBA; CEO & Chairman of MAIA Biotechnology, was a guest on Benzinga’s All Access.
MAIA is a targeted therapy immuno-oncology company focused on developing and commercializing drugs targeting cancers with novel mechanisms of action.
The company’s lead program is THIO. The novel therapy “opens” the telomere cap of cancerous DNA, leading to rapid cell death.
MAIA is a targeted therapy immuno-oncology company focused on developing and commercializing drugs targeting cancers with novel mechanisms of action.
The company’s lead program is THIO. The novel therapy “opens” the telomere cap of cancerous DNA, leading to rapid cell death.